Site Under Construction

The economic burden of psoriasis: a cross-sectional study in a tertiary hospital in the Philippines

Diandra Aurora R. Zabala, MD, DPDS, Victoria P. Guillano, MD, FPDS, Maynie Bambi D. Lugasan, MD, DPDS



Costs associated with chronic psoriasis impart a significant economic burden.



This study aims to determine the direct and indirect costs of psoriasis patients in a tertiary government hospital in Davao City.



Plaque-type psoriasis patients who were actively seeking care at the Southern Philippines Medical Center Department of Dermatology for at least 6 months prior to the study period were included. The participants reported on socioeconomic status, productivity loss and monetary funding through questionnaires. Work impairment was evaluated using the Work Productivity and Activity Impairment questionnaire and was used to compute the indirect cost. A 6-month retrospective review of the health information system and medical charts generated the healthcare resource utilization data as well as the medical data used to compute the direct cost.



Among the 43 participants enrolled, 53% had a monthly household income of less than PHP8,000 (USD157) and 27% were unemployed. There was an overall work impairment of 65.4%, and 55% had experienced a change in employment status due to psoriasis. The mean 6-month direct cost of psoriasis was PHP22,672.28 ($445). The mean 6-month indirect cost was PHP 26,071.20 ($511) for employment status change and PHP 75,804.30 ($1,486) for work impairment. Government agencies provided financial aid for treatment but majority of the costs came from the participants’ own pockets.



The economic burden of psoriasis increased substantially due to the indirect cost, which in turn increased remarkably due to work impairment and employment status change.


  1. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leff ell DJ, Wolff K. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012.
  2. Dizon AB, Pasion CRF, Perez-Chua T, Copuyoc-Sampedro CM, et al. (2020). PDS Top 10 Diseases Based on New and Existing Cases. Skin Contact: The Offi cial Newsletter of the Philippine Dermatological Society. Available from
  3. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010 Aug;146(8):891-5.
  4. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016 Feb; 17(1):87-97.
  5. Alcusky M, Lee S, Lau G, et al. Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis. Dermatol Ther (Heidelb). 2017 Dec; 7(4): 463–483.
  6. Kamangar F, Isip L, Bhutani T, Dennis M, Heller MM, Lee ES, Nie H, Liao W. How Psoriasis Patients Perceive, Obtain, and Use Biologic Agents: Survey from an Academic Medical Center. J Dermatolog Treat. 2013 Feb; 24(1): 13–24.
  7. Schaefer CP, Cappelleri JC, Cheng R, Cole JC, Guenthner S, Fowler J, Johnson S, Mamolo C. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015 Oct;73(4):585-593.e3.
  8. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007; 57(6):963-71.
  9. Kruntorádová, K., Klimeš, J., Šedová, L., Štolfa, J., Doležal, T., & Petříková, A. (2014). Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis. Value in Health Regional Issues, 4, 100–106.
  10. Changik Jo. Cost-of-illness studies: concepts, scopes and methods. Clin Mol Hepatol. 2014 Dec; 20(4): 327–337.
  11. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: A replication and update. Health Care Financ Rev. 1985 Fall; 7(1): 61–80.
  12. Clabaugh G, Ward MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health. 2008 Jan-Feb;11(1):13-21.
  13. Byford S, Torgerson DJ, Raftery J. Economic note: Cost of illness studies. BMJ. 2000 May 13; 320(7245): 1335.
  14. Corso, Phaedra S.(2016). Cost of illness: the second of a five-part series. Centers for Disease Control and Prevention. Available from:
  15. Mustonen A. Psoriasis Causes Significant Economic Burden to Patients. Dermatol Ther (Heidelb). 2014 Jun; 4(1): 115–124.
  16. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol.2010;146(1):46–54.
  17. Reilly MC, Zbrozek AS, Dukes E. The validity and reproducibility of a work productivity and activity impairment measure. PharmacoEconomics 1993; 4(5):353-365.
  18. Gupta S, Isherwood G, Jones K, Van Impe K. Productivity loss and resource utilization, and associated indirect and direct costs in individuals providing care for adults with schizophrenia in the EU5. Clinicoecon Outcomes Res. 2015 Nov 25;7:593-602.
  19. Fabian MAM, Concha MEA. Level of bronchial asthma control and direct medical care costs among adult asthma club members: longitudinal cost of illness study. SPMC J Health Care Serv. 2015;1(1):25¬30.
  20. Global Report on Psoriasis. (2016) World Health Organization. Available from;jsessionid=54912784D28C9F36ECCD45471AC5775B?sequence=1. Accessed 24 Mar 2019.
  21. Puig L, van de Kerkhof PCM, Reich K, Bachelez H, Barker J, Girolomoni G, Paul C. A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1176-1182.
  22. Lynde CW, Poulin Y, Guenther L, Jackson C. The burden of psoriasis in Canada: insights from the psoriasis knowledge in Canada (SKIN) survey. J Cutan Med Surg. 2009 Sep-Oct;13(5):235-52.
  23. Strober B, Greenberg JD, Karki C, Mason M, Guo N, Hur P, Zhao Y, Herrera V, Lin F, Lebwohl M. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019 Apr 20;9(4):e027535.
  24. Ng JN, Guevara BE, Guillano V. Demographic and clinical profi les of adult Filipino patients with psoriasis in Davao City: A cross-sectional study. J Phil Dermatol Soc. 2018; 27(1): 41-63 Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014 Jul;13(7):848-53
  25. Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, Chan D. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol. 2010 Dec;49(12):1368-75.
  26. Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017 Nov; 18(11): 2297.
  27. Mahler R, Jackson C, Ijacu H. The burden of psoriasis and barriers to refractory care: Results from a Canadian patient survey. J Cutan Med Surg. 2009 Nov-Dec;13(6):283-93.
  28. Burgos-Pol R, Martinez-Sesmero JM, Ventura-Cerda JM, Elias I, Caloto MT, Casado MA. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas Dermosifi liogr. 2016 Sep;107(7):577-90.
  29. Yoshimoto T, Oka H, Fujii T, Nagata T, Matsudaira K. The economic burden of lost productivity due to presenteeism caused by health conditions among workers In Japan. J Occup Environ Med. 2020 Oct; 62(10): 883–888.
  30. Collins JJ, Baase CM, Sharda CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med 2005; 47:547–557.
  31. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions aff ecting U.S. employers. J Occup Environ Med 2004; 46:398–412.
  32. Iverson D, Lewis KL, Caputi P, Knospe S. The cumulative impact and associated costs of multiple health conditions on employee productivity. J Occup Environ Med 2010; 52:1206–1211.
  33. Tarricone, R. (2006). Cost-of-illness analysis. Health Policy, 77(1), 51–63. doi: 10.1016/j.healthpol.2005.07.016.

REquesting Permission

The economic burden of psoriasis: a cross-sectional study in a tertiary hospital in the Philippines